AnorMED, Inc.

Hematology-focused biotech firm exercises underwriters' option

Published in Lab Business Week, January 8th, 2006

AnorMED, Inc., (AOM) has received notice that the underwriters have exercised their option to purchase 1,250,000 common shares for gross proceeds of $5,000,000 and have exercised their over-allotment option to purchase an additional 1,125,000 common shares for further gross proceeds of $4,500,000.

The options were granted pursuant to an agreement with an underwriting syndicate co-led by Raymond James, Ltd., and BMO Nesbitt Burns, Inc., and including CIBC World Markets, Inc., and Canaccord Capital Corp. under which the underwriters have agreed to purchase 6,250,000 common shares from AnorMED and sell to the public at a price of $4.00 per common share, representing an...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-01-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry